研究单位：[1]Peking Union Medical College Hospital[2]Dizal Pharmaceuticals[3]Beijing Cancer Hospital,Beijing,China[4]Beijing Chest Hospital，Capital Medical University,Beijing,China[5]Peking Union Medical College Hospital,Beijing,China[6]Peking University Third Hospital,Beijing,China[7]Jilin Cancer Hospital,Chang chun,China[8]Hunan Cancer Hospital(The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University,Changsha,China[9]West China Hospital of Sichuan University,Chengdu,China[10]Army Medical Center of PLA,Chongqing,China[11]Chongqing University Cancer Hospital(Chongqing Cancer Hospital),Chongqing,China[12]The First Affiliated Hospital of Guangzhou Medical University,Guangzhou,China[13]The First Affiliated Hospital, Sun Yat-sen University,Guangzhou,China[14]Hainan General Hospital,Haikou,China[15]The First Affiliated Hospital Zhejiang University School of Medicine,Hangzhou,China[16]The Second Affiliated Hospital Zhejiang University School of Medicine,Hangzhou,China[17]Zhejiang Cancer Hospital (Cancer Hospital of the University of Chinese Academy of Sciences),Hangzhou,China[18]Harbin Medical University Cancer Hospital,Harbin,China[19]The Second Hospital of Anhui Medical University,Hefei,China[20]The Affiliated Hospital of Inner Mongolia Medical University,Hohhot,China[21]Jinan Central Hospital (Central Hospital Affiliated to Shandong First Medical University),Jinan,China[22]Yunnan Cancer Hospital,Kunming,China[23]The First Affiliated Hospital of Nanchang University,Nanchang,China[24]The Second Affiliated Hospital of Nanchang University,Nanchang,China[25]Fudan University Shanghai Cancer Center,Shanghai,China[26]The First Hospital of China Medical University,Shenyang,China[27]The Fourth Hospital of Hebei Medical University,Shijiazhuang,China[28]The First Affiliated Hospital of Soochow University,Suzhou,China[29]Shanxi Provincial Cancer Hospital,Taiyuan,China[30]Tianjin Medical University Cancer Institute & Hospital,Tianjin,China[31]Hubei Cancer Hospital,Wuhan,China[32]Union Hospital Tongji Medical College Huazhong University of Science and Technology,Wuhan,China[33]The First Affiliated Hospital of Xi''an Jiaotong University,Xi''an,China[34]Affiliated Cancer Hospital of Zhengzhou University(Henan Cancer Hospital),Zhengzhou,China[35]The Affiliated Cancer Hospital of Xinjiang Medical University,Ürümqi,China
研究目的：
This is a Phase II, single-arm, multi-center clinical study to evaluate the anti-tumor efficacy, safety, tolerability and pharmacokinetics of DZD9008 in participants with locally advanced or metastatic NSCLC carrying EGFR exon 20 insertion mutations whose disease has progressed on prior platinum-based chemotherapy
